Whereas frequent TP53 loss of function mutations in basal-like breast cancer could increase retrotransposon expression and the associated IFN response, the TP53 gain of function mutations in high-grade serous ovarian tumors could reduce retrotransposon expression and its associated IFN response [86]. This evidence concerns the gene TP53 and breast cancer.